Margaret Dugan - Feb 28, 2022 Form 4 Insider Report for BeiGene, Ltd. (BGNE)

Role
Director
Signature
/s/ Qing Nian, as Attorney-in-Fact
Stock symbol
BGNE
Transactions as of
Feb 28, 2022
Transactions value $
$0
Form type
4
Date filed
3/2/2022, 04:07 PM
Previous filing
Feb 8, 2022
Next filing
Jun 24, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BGNE Share Option (Right to Buy) Award $0 +22.6K $0.00 22.6K Feb 28, 2022 Ordinary Shares 22.6K $16.22 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.
F2 The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.